![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NAMPT |
Gene summary for NAMPT |
![]() |
Gene information | Species | Human | Gene symbol | NAMPT | Gene ID | 10135 |
Gene name | nicotinamide phosphoribosyltransferase | |
Gene Alias | 1110035O14Rik | |
Cytomap | 7q22.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R718 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10135 | NAMPT | GSM4909281 | Human | Breast | IDC | 1.29e-09 | -4.37e-01 | 0.21 |
10135 | NAMPT | GSM4909282 | Human | Breast | IDC | 4.52e-10 | -4.00e-01 | -0.0288 |
10135 | NAMPT | GSM4909285 | Human | Breast | IDC | 1.88e-13 | -4.70e-01 | 0.21 |
10135 | NAMPT | GSM4909286 | Human | Breast | IDC | 4.76e-18 | -5.48e-01 | 0.1081 |
10135 | NAMPT | GSM4909287 | Human | Breast | IDC | 6.48e-07 | -3.93e-01 | 0.2057 |
10135 | NAMPT | GSM4909290 | Human | Breast | IDC | 1.21e-05 | -4.33e-01 | 0.2096 |
10135 | NAMPT | GSM4909291 | Human | Breast | IDC | 1.70e-07 | -4.85e-01 | 0.1753 |
10135 | NAMPT | GSM4909293 | Human | Breast | IDC | 8.04e-04 | -2.38e-01 | 0.1581 |
10135 | NAMPT | GSM4909294 | Human | Breast | IDC | 9.38e-10 | -3.96e-01 | 0.2022 |
10135 | NAMPT | GSM4909296 | Human | Breast | IDC | 5.19e-11 | -3.36e-01 | 0.1524 |
10135 | NAMPT | GSM4909297 | Human | Breast | IDC | 9.06e-34 | -6.35e-01 | 0.1517 |
10135 | NAMPT | GSM4909298 | Human | Breast | IDC | 1.25e-21 | -5.97e-01 | 0.1551 |
10135 | NAMPT | GSM4909301 | Human | Breast | IDC | 1.66e-10 | -4.63e-01 | 0.1577 |
10135 | NAMPT | GSM4909302 | Human | Breast | IDC | 5.41e-04 | -3.21e-01 | 0.1545 |
10135 | NAMPT | GSM4909304 | Human | Breast | IDC | 3.27e-03 | -3.78e-01 | 0.1636 |
10135 | NAMPT | GSM4909306 | Human | Breast | IDC | 4.13e-12 | -5.11e-01 | 0.1564 |
10135 | NAMPT | GSM4909307 | Human | Breast | IDC | 6.15e-26 | -6.28e-01 | 0.1569 |
10135 | NAMPT | GSM4909308 | Human | Breast | IDC | 1.15e-05 | -3.76e-01 | 0.158 |
10135 | NAMPT | GSM4909309 | Human | Breast | IDC | 2.02e-08 | -4.03e-01 | 0.0483 |
10135 | NAMPT | GSM4909311 | Human | Breast | IDC | 6.20e-46 | -7.02e-01 | 0.1534 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000762325 | Thyroid | ATC | circadian rhythm | 100/6293 | 210/18723 | 1.67e-05 | 1.54e-04 | 100 |
GO:000974333 | Thyroid | ATC | response to carbohydrate | 114/6293 | 253/18723 | 9.26e-05 | 6.81e-04 | 114 |
GO:009039814 | Thyroid | ATC | cellular senescence | 49/6293 | 93/18723 | 1.13e-04 | 8.08e-04 | 49 |
GO:001050713 | Thyroid | ATC | negative regulation of autophagy | 44/6293 | 85/18723 | 4.13e-04 | 2.49e-03 | 44 |
GO:003428432 | Thyroid | ATC | response to monosaccharide | 100/6293 | 225/18723 | 4.39e-04 | 2.62e-03 | 100 |
GO:009034211 | Thyroid | ATC | regulation of cell aging | 33/6293 | 61/18723 | 7.76e-04 | 4.28e-03 | 33 |
GO:003300214 | Thyroid | ATC | muscle cell proliferation | 107/6293 | 248/18723 | 1.03e-03 | 5.47e-03 | 107 |
GO:190129318 | Thyroid | ATC | nucleoside phosphate biosynthetic process | 110/6293 | 256/18723 | 1.06e-03 | 5.58e-03 | 110 |
GO:000916518 | Thyroid | ATC | nucleotide biosynthetic process | 109/6293 | 254/18723 | 1.17e-03 | 6.15e-03 | 109 |
GO:000974632 | Thyroid | ATC | response to hexose | 95/6293 | 219/18723 | 1.56e-03 | 7.92e-03 | 95 |
GO:004865916 | Thyroid | ATC | smooth muscle cell proliferation | 81/6293 | 184/18723 | 2.02e-03 | 9.60e-03 | 81 |
GO:2000772 | Thyroid | ATC | regulation of cellular senescence | 28/6293 | 53/18723 | 3.01e-03 | 1.36e-02 | 28 |
GO:004866016 | Thyroid | ATC | regulation of smooth muscle cell proliferation | 78/6293 | 180/18723 | 4.00e-03 | 1.73e-02 | 78 |
GO:000756517 | Thyroid | ATC | female pregnancy | 82/6293 | 193/18723 | 6.04e-03 | 2.42e-02 | 82 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046219 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462114 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046212 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa0462111 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462121 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462131 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa046214 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046215 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa04621 | Stomach | WIM | NOD-like receptor signaling pathway | 15/284 | 186/8465 | 1.44e-03 | 1.30e-02 | 1.04e-02 | 15 |
hsa046211 | Stomach | WIM | NOD-like receptor signaling pathway | 15/284 | 186/8465 | 1.44e-03 | 1.30e-02 | 1.04e-02 | 15 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | DCIS |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Healthy |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | Healthy |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | IDC |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | IDC |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Precancer |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | Precancer |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Cervix | ADJ |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Healthy |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Precancer |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Cervix | Precancer |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | CRC | ADJ |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | CRC |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | CRC | CRC |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | FAP |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | Healthy |
Page: 1 2 3 4 5 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAMPT | SNV | Missense_Mutation | novel | c.397N>C | p.Thr133Pro | p.T133P | P43490 | protein_coding | deleterious(0) | possibly_damaging(0.497) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
NAMPT | SNV | Missense_Mutation | c.318N>C | p.Glu106Asp | p.E106D | P43490 | protein_coding | tolerated(0.48) | benign(0) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
NAMPT | SNV | Missense_Mutation | c.1237N>C | p.Val413Leu | p.V413L | P43490 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
NAMPT | SNV | Missense_Mutation | novel | c.722N>T | p.Ser241Phe | p.S241F | P43490 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
NAMPT | SNV | Missense_Mutation | novel | c.182N>T | p.Gly61Val | p.G61V | P43490 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
NAMPT | SNV | Missense_Mutation | c.857N>T | p.Ala286Val | p.A286V | P43490 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NAMPT | SNV | Missense_Mutation | novel | c.1211T>C | p.Val404Ala | p.V404A | P43490 | protein_coding | tolerated(0.74) | benign(0.096) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
NAMPT | SNV | Missense_Mutation | c.686A>C | p.Lys229Thr | p.K229T | P43490 | protein_coding | tolerated(0.09) | possibly_damaging(0.49) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NAMPT | SNV | Missense_Mutation | c.571N>A | p.His191Asn | p.H191N | P43490 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A0GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NAMPT | SNV | Missense_Mutation | novel | c.238N>G | p.Ile80Val | p.I80V | P43490 | protein_coding | tolerated(0.21) | probably_damaging(0.94) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10135 | NAMPT | DRUGGABLE GENOME | GMX1777 | TEGLARINAD CHLORIDE | ||
10135 | NAMPT | DRUGGABLE GENOME | GMX1777 | TEGLARINAD CHLORIDE | ||
10135 | NAMPT | DRUGGABLE GENOME | CHS-828 | CHS-828 | ||
10135 | NAMPT | DRUGGABLE GENOME | Daporinad | DAPORINAD | ||
10135 | NAMPT | DRUGGABLE GENOME | inhibitor | CHEMBL190412 | TEGLARINAD CHLORIDE |
Page: 1 |